 Hi, I'm Claire Snyder, a Ph.D. Outcomes and Health Services Researcher and a Professor of Medicine, Oncology, and Health Policy and Management at the Johns Hopkins Schools of Medicine and Public Health. And I'm Mike Brundage. I'm a Radiation Oncologist and Health Services Researcher and Director of the Cancer Care and Epidemiology Division at the Queen's Cancer Research Institute in Kingston, Canada. Together, we lead the Proteus Consortium. Proteus stands for Patient-Aported Outcomes Schools, Engaging Users and Spakeholders. Proteus' goal is that patients, clinicians, and other decision makers have the pro-data they need for research studies and clinical care so that they can make the best decisions possible about treatment options. To accomplish this objective, Proteus is partnering with 37 key patient, clinician, research, health system, funding, and regulatory groups from the U.S. and the International. In particular, for pro-data from research studies to be most useful, the pro-specific methods of those studies must be specified appropriately, the pros must be measured effectively, the data have to be analyzed properly, and the results have to be reported clearly, all so that the findings can be applied effectively in practice. Over the past decade, several methodological tools have been developed to address each of these aspects of quality pros and research studies, including tools developed by the work of the initial CISACOL initiative and now CISACOL IMI. Proteus is pleased to be partnering with CISACOL IMI to promote the implementation and dissemination of its guidance, along with the other methodologic tools for effectively implementing pros and research studies and then clinical care. For more information about Proteus, please visit our website at theproteusconsortion.org.